Brief: Altamira Therapeutics Provides Business Update

Altamira Therapeutics

27/01/2023 14:16

Jan 27 (Reuters) - Altamira Therapeutics Ltd  CYTO.O :
    * ALTAMIRA THERAPEUTICS PROVIDES BUSINESS UPDATE
    * ALTAMIRA THERAPEUTICS LTD - RESTRUCTURING OF FIVET
CONVERTIBLE
LOAN INCLUDING EXTENSION OF MATURITY
    * ALTAMIRA THERAPEUTICS LTD - PROCESS FOR DIVESTITURE /
PARTNERING
OF LEGACY ASSETS CONTINUES
    * ALTAMIRA THERAPEUTICS LTD - CASE FOR BENTRIO'S PROTECTIVE
EFFECT
IN VIRAL INFECTION PROPHYLAXIS STILL INTACT
    * ALTAMIRA THERAPEUTICS LTD - REMAINS COMMITTED TO ITS
PRIMARY
CORPORATE STRATEGY TO FOCUS EXCLUSIVELY ON RNA DELIVERY
    * ALTAMIRA THERAPEUTICS LTD - BOARD OF DIRECTORS HAS TAKEN
MEASURES TO ENHANCE ITS FINANCIAL FLEXIBILITY
    * ALTAMIRA THERAPEUTICS LTD - PURSUING A DIVESTITURE OR
PARTNERING
TRANSACTION FOR INNER EAR ASSETS WITH OTHER PARTIES
    * ALTAMIRA THERAPEUTICS LTD - STRIVING TO SELL OR PARTNER
ITS
OTHER LEGACY ASSETS - INNER EAR THERAPEUTICS
    * ALTAMIRA THERAPEUTICS - UNDER NEWLY AMENDED TERMS OF
CONVERTIBLE
LOAN AGREEMENT, MATURITY IS EXTENDED FROM FEBRUARY 8, 2023 TO
MARCH 15, 2023
    * ALTAMIRA THERAPEUTICS-AGREED WITH FIVET TO RESTRUCTURE
CERTAIN
TERMS,CONDITIONS OF CHF 5 MILLION CONVERTIBLE LOAN WHICH IT HAD
GRANTED TO CO IN FEB 2022
    * ALTAMIRA THERAPEUTICS - AGREED UPON SALE OF ASSETS TO A
EUROPEAN
FAMILY OFFICE DID NOT CLOSE AS BUYER WAS NOT ABLE TO SECURE
FINANCING

Source text for Eikon:  ID:nGNX6hyv6m 
Further company coverage:  CYTO.O 
 ((Reuters.Briefs@thomsonreuters.com;;))